Literature DB >> 16766237

Total parenteral nutrition-related gastroenterological complications.

F W Guglielmi1, D Boggio-Bertinet, A Federico, G B Forte, A Guglielmi, C Loguercio, S Mazzuoli, M Merli, A Palmo, C Panella, L Pironi, A Francavilla.   

Abstract

Total parenteral nutrition is a life saving therapy for patients with chronic gastrointestinal failure, being an effective method for supplying energy and nutrients when oral or enteral feeding is impossible or contraindicated. Clinical epidemiological data indicate that total parenteral nutrition may be associated with a variety of problems. Herein we reviewed data on the gastroenterological tract regarding: (i) total parenteral nutrition-related hepatobiliary complications; and (ii) total parenteral nutrition-related intestinal complications. In the first group, complications may vary from mildly elevated liver enzyme values to steatosis, steatohepatitis, cholestasis, fibrosis and cirrhosis. In particular, total parenteral nutrition is considered to be an absolute risk factor for the development of biliary sludge and gallstones and is often associated with hepatic steatosis and intrahepatic cholestasis. In general, the incidence of total parenteral nutrition-related hepatobiliary complications has been reported to be very high, ranging from 20 to 75% in adults. All these hepatobiliary complications are more likely to occur after long-term total parenteral nutrition, but they seem to be less frequent, and/or less severe in patients who are also receiving oral feeding. In addition, end-stage liver disease has been described in approximately 15-20% of patients receiving prolonged total parenteral nutrition. Total parenteral nutrition-related intestinal complications have not yet been adequately defined and described. Epidemiological studies intended to define the incidence of these complications, are still ongoing. Recent papers confirm that in both animals and humans, total parenteral nutrition-related intestinal complications are induced by the lack of enteral stimulation and are characterised by changes in the structure and function of the gut. Preventive suggestions and therapies for both these gastroenterological complications are reviewed and reported in the present review.

Entities:  

Mesh:

Year:  2006        PMID: 16766237     DOI: 10.1016/j.dld.2006.04.002

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  14 in total

1.  Application of acellular dermal matrix for intestinal elongation in animal models.

Authors:  Hui-Min Xu; Zhen-Jun Wang; Jia-Gang Han; Hua-Chong Ma; Bo Zhao; Bao-Cheng Zhao
Journal:  World J Gastroenterol       Date:  2010-04-28       Impact factor: 5.742

2.  Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates.

Authors:  Andreas Vegge; Thomas Thymann; Pernille Lund; Barbara Stoll; Stine B Bering; Bolette Hartmann; Jacob Jelsing; Niels Qvist; Douglas G Burrin; Palle B Jeppesen; Jens J Holst; Per T Sangild
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-06-13       Impact factor: 4.052

Review 3.  Chronic intestinal pseudo-obstruction.

Authors:  Alexandra Antonucci; Lucia Fronzoni; Laura Cogliandro; Rosanna-F Cogliandro; Carla Caputo; Roberto De Giorgio; Francesca Pallotti; Giovanni Barbara; Roberto Corinaldesi; Vincenzo Stanghellini
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

Review 4.  Animal models of gastrointestinal and liver diseases. Animal models of infant short bowel syndrome: translational relevance and challenges.

Authors:  Per T Sangild; Denise M Ney; David L Sigalet; Andreas Vegge; Douglas Burrin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-10-23       Impact factor: 4.052

5.  Incidence of nutritional support complications in patient hospitalized in wards. multicentric study.

Authors:  Gloria María Agudelo; Nubia Amparo Giraldo; Nora Luz Aguilar; Beatriz Elena Restrepo; Marcela Vanegas; Sandra Alzate; Mónica Martínez; Sonia Patricia Gamboa; Eliana Castaño; Janeth Barbosa; Juliana Román; Angela María Serna; Gloria Marcela Hoyos
Journal:  Colomb Med (Cali)       Date:  2012-06-30

6.  Hepatic steatosis and steatohepatitis: Are they really two distinct entities?

Authors:  Cory M Fielding; Paul Angulo
Journal:  Curr Hepatol Rep       Date:  2014-06-01

7.  Impact of Clinical Factors on the Intestinal Microbiome in Infants With Gastroschisis.

Authors:  Allison J Wu; David J Lee; Fan Li; Nicole H Tobin; Grace M Aldrovandi; Stephen B Shew; Kara L Calkins
Journal:  JPEN J Parenter Enteral Nutr       Date:  2020-06-26       Impact factor: 3.896

Review 8.  Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease.

Authors:  Liane Rabinowich; Oren Shibolet
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

9.  Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome.

Authors:  Miguel A Lanaspa; Takuji Ishimoto; Nanxing Li; Christina Cicerchi; David J Orlicky; Philip Ruzycki; Philip Ruzicky; Christopher Rivard; Shinichiro Inaba; Carlos A Roncal-Jimenez; Elise S Bales; Christine P Diggle; Aruna Asipu; J Mark Petrash; Tomoki Kosugi; Shoichi Maruyama; Laura G Sanchez-Lozada; James L McManaman; David T Bonthron; Yuri Y Sautin; Richard J Johnson
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Epidemiology of gallbladder disease: cholelithiasis and cancer.

Authors:  Laura M Stinton; Eldon A Shaffer
Journal:  Gut Liver       Date:  2012-04-17       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.